[
  {
    "ts": null,
    "headline": "Looking at the Changing Narrative for Biogen After Recent Pipeline and Market Developments",
    "summary": "Biogen’s fair value estimate has inched up from $170.03 to $172.34, reflecting a slight improvement in the company’s intrinsic valuation. This update comes as analysts weigh recent progress in Biogen’s business and pipeline, while also considering continuing industry and regulatory uncertainty. Stay tuned to discover how you can keep track of the evolving narrative around Biogen’s stock outlook. What Wall Street Has Been Saying Recent analyst updates on Biogen have reflected a mix of optimism...",
    "url": "https://finnhub.io/api/news?id=638cd6fac8fc3a61de0204b5cdd4dafa24468131fbff85df3fd94dd59744ad1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760613021,
      "headline": "Looking at the Changing Narrative for Biogen After Recent Pipeline and Market Developments",
      "id": 137104882,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen’s fair value estimate has inched up from $170.03 to $172.34, reflecting a slight improvement in the company’s intrinsic valuation. This update comes as analysts weigh recent progress in Biogen’s business and pipeline, while also considering continuing industry and regulatory uncertainty. Stay tuned to discover how you can keep track of the evolving narrative around Biogen’s stock outlook. What Wall Street Has Been Saying Recent analyst updates on Biogen have reflected a mix of optimism...",
      "url": "https://finnhub.io/api/news?id=638cd6fac8fc3a61de0204b5cdd4dafa24468131fbff85df3fd94dd59744ad1e"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons BIIB is Risky and 1 Stock to Buy Instead",
    "summary": "Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 26.6% to $146 per share while the index has gained 26.5%.",
    "url": "https://finnhub.io/api/news?id=1ef8bf08cc5ebb080d95aa94a75764b97720c24a8a3a1be4b5622abc52a06e1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760587529,
      "headline": "3 Reasons BIIB is Risky and 1 Stock to Buy Instead",
      "id": 137104883,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 26.6% to $146 per share while the index has gained 26.5%.",
      "url": "https://finnhub.io/api/news?id=1ef8bf08cc5ebb080d95aa94a75764b97720c24a8a3a1be4b5622abc52a06e1e"
    }
  }
]